Feasibility of human T-lymphotropic virus type I screening using pooled sera

Journal of the Formosan Medical Association

Volumn 101, Issue 11, 2002, Pages 775-778

  Chang, Chao Sung ^a   Wu, Ya Wen ^a   Pan, Ya Chun ^a   Chen, Zi Yue ^a   Wang, Ching Shan ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Blood donors; Human T cell lymphotropic virus type I; Pooled sera

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CONTROLLED STUDY; COST CONTROL; DILUTION; ENZYME IMMUNOASSAY; FEASIBILITY STUDY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; MAJOR CLINICAL STUDY; MASS SCREENING; NONHUMAN; PROSPECTIVE STUDY; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; TAIWAN; VOLUNTEER; WESTERN BLOTTING;

BLOOD SPECIMEN COLLECTION; BLOTTING, WESTERN; FEASIBILITY STUDIES; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MASS SCREENING; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; TAIWAN;

EID: 0036867338     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Osame M, Matsumoto M, Usuku K, et al: Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T cell leukemia-like cells. Ann Neurol 1987;21:117-22.
2. Yamaguchi K: Human T-lymphotropic virus type I in Japan. Lancet 1994;343:213-6.
3. Iwata K, Ito S, Saito H, et al: Mortality among inhabitants of an HTLV-I endemic area in Japan. Jpn J Cancer Res 1994;85:231-7.
4. Kajiyama W, Kashiwagi S, Ikematsu H, et al: Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 1986;154:851-7.
5. Tajima K, Takezaki T, Ito M, et al: Short term breast feeding may reduce the risk of vertical transmission of HTLV-I. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:285.
6. Okochi K, Sato H, Hinuma Y: A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984; 46:245-53.
7. Kamihira S, Nakasima S, Oyakawa Y, et al: Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors. Vox Sang 1987:52:43-4.
8. Tynell E, Andersson S, Lithander E, et al: Screening for human T cell leukemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis. BMJ 1998; 316:1417-22.
9. Wang CH, Chen CJ, Hu CY, et al: Seroepidemiology of human T cell lymphotropic virus type I infection in Taiwan. Cancer Res 1988;48:5042-4.
10. Canavaggio M, Leckie G, Allain JP, et al: The prevalence of antibody to HTLV-I/II in United States plasma donors and in United States and French hemophiliacs. Transfusion 1990;30:780-2.
11. Defer C, Coste J, Descamps F, et al: Contribution of polymerase chain reaction and radioimmunoprecipitation assay in the confirmation of human T-lymphotropic virus infection in French blood donors. Transfusion 1995;35: 596-600.
12. Busch MP, Laycock M, Kleiman SH, et al: Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study. Blood 1994;83: 1143-8.
13. Pagliuca A, Pawson R, Mufti GJ: HTLV-I screening in Britain. BMJ 1995;311:1313-4.
14. Chang CS, Wu YW, Pan YC, et al: Low seroprevalence of human T-cell lymphtropic virus type I infection among volunteer blood donors in Taiwan. Transfusion 1998;38: 1118-9.
15. Tamoshiro H, Maskill W, Emmanuel J, et al: Reducing the cost of HIV testing. Lancet 1993;342:87-90.
16. Emmanuel JC, Bassett MT, Smith HJ, et al: Pooling of sera for human immunodeficiency virus (HIV) testing: an economical method for use in developing countries. J Clin Pathol 1988;41:582-5.
17. Carhoon-Young B, Chandler A, Livermore T, et al: Sensitivity and specificity of pooled versus individual sera in human immunodeficiency virus antibody prevalence study. J Clin Microbiol 1989;27:1893-5.
18. Behets F, Bertozzi S, Kasali M, et al: Successful use of pooled sera to determine HIV-1 seroprevalence in Zaire with development of cost efficiency models. AIDS 1990;4: 737-41.
19. Anderson S, Gessain A, Taylor GP: Pooling of samples for seroepidemiological surveillance of human T-cell lymphotropic virus types I and II. Virus Res 2001;78:101-6.
20. Dickmeiss E, Christiansen AH, Smith E: Risk of disease transmission via donor blood in Denmark at the turn of the century. Ugeskr Laeger 2001;163:2628-32. [In Danish; English abstract]
21. Wang JT, Lin MT, Chen PJ, et al: Transfusion-transmitted human T-cell lymphotropic virus type I infections in Taiwan: a true risk and occasional coinfection with hepatitis C virus shown in a prospective study. Blood 1994;84: 934-40.
22. Inaba S, Okochi K, Sato H, et al: Efficacy of donor screening for HTLV-I and the natural history of transfusion-transmitted infection. Transfusion 1999; 39:1104-10.
23. Liu H, Shah M, Stramer SL, et al: Sensitivity and specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain reaction and several serologic assays in screening a population with a high prevalence of HTLV-II. Transfusion 1999;39:1185-93.